This phase I/II study evaluated high-dose treosulfan in patients with high-grade lymphoma. In all, 21 patients (median age 51, 25-60 years) with primary refractory disease (n ¼ 3) or early (n ¼ 11) or late (n ¼ 7) relapse received DexaBEAM and one course etoposide for cytoreduction and PBPC mobilization. Subsequently, 16 patients received 30 g/m 2 treosulfan and 140 mg/m 2 melphalan, followed by autologous transplantation. Nine patients received a 2nd high-dose treatment (HDT) with 30 g/m 2 treosulfan and 750 mg/m 2 thiotepa. Recovery time to 41/nl leukocytes and 425/nl thrombocytes was 8.9 (range 8-11) and 11.9 (8-16) days after 1st and 9.6 (7-13) and 13 (9-19) days after 2nd HDT. Reversible grade 3 or 4 nonhematologic toxicities included mucositis (n ¼ 7), infection (n ¼ 7) and one episode of re-entry tachycardia. Two treatment-related deaths occurred after 2nd HDT. Since three dose-limiting toxicities occurred among nine patients receiving tandem HDT, 30 g/m 2 of treosulfan was considered MTD in this setting. Patients with late compared to early relapse or refractory disease had a higher probability of CR (6/7 vs 3/14 patients, P ¼ 0.017) and overall survival (71 vs 21%, Po0.05, 24-49 months follow-up). In conclusion, high-dose treosulfan as major therapy component induces sustained complete remissions in relapsed high-grade lymphoma with acceptable toxicity.
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High-dose chemotherapy with autologous stem cell transplantation can achieve long-term remission in patients with relapsed high-grade lymphoma. 1, 2 Frequently employed cytostatic agents include cyclophosphamide, etoposide, melphalan, BCNU, cytarabine and platinum compounds. The alkylating drug busulfan has been used for 30 years in high-dose therapy. It is characterized by profound stem cell toxicity and cytotoxic activity in various hematological malignancies. 3 Major drawbacks associated with busulfan include the high incidence of veno-occlusive disease (VOD), 4 ,5 a high variance of bioavailability, drug interactions associated with enzymatic activation in the liver 6, 7 and finally a decreased threshold of seizure activity. 8 Treosulfan is a prodrug of a bifunctional alkylating cytotoxic agent with close structural similarity to busulfan, 9 which has been used for the treatment of ovarian cancer for many years. 10, 11 Myeloablative dose escalation up to 56 g/ m 2 has recently been tested, and the maximum-tolerated dose (MTD) is 47 g/m 2 . 12 Treosulfan can be given intravenously (i.v.) and is activated nonenzymatically, yielding highly reproducible pharmacokinetic profiles. 13 Owing to its antineoplastic activity and limited organ toxicity, high-dose treosulfan has been considered for autologous peripheral blood stem cell transplantation. Recent in vitro data show activity in myeloma cells. 14 Profound stem cell toxicity has been demonstrated in a preclinical model and it has been hypothesized that treosulfan, similar to busulfan, may also kill immature malignant progenitor cells. 15 Most recently, treosulfan has been combined with fludarabine as a conditioning treatment in allogeneic stem cell transplantation. 16 In the following phase I/II trial for patients with relapsed and refractory high-grade lymphoma, we tested the feasibility, the MTD, and the efficacy of high-dose treosulfan in a tandem high-dose approach.
Materials and methods

Patient selection
The study was open to adults up to 60 years of age with relapsed or refractory high-grade lymphoma who had received chemotherapy with or without radiotherapy for their primary lymphoma manifestation. Patients were considered refractory to the primary treatment if they never achieved at least PR. Early or late relapse was defined as relapse within or beyond 1 year after primary diagnosis. 2 Patients with antecedent or concurrent neoplastic disease were excluded. The protocol was started in October 1999 after approval by the local ethical committee. Patients were treated after giving written informed consent.
Induction therapy and stem cell mobilization
For cytoreduction and stem cell mobilization (back-up), all patients were scheduled to receive one cycle of DexaBEAM with dexamethasone 3 Â 8 mg on treatment days 1-10, BCNU 60 mg/m 2 on day 2, melphalan 20 mg/m 2 on day 3, etoposide 75 mg/m 2 and cytarabine 100 mg/m 2 every 12 h, each on days 4-7. Filgrastim at 10 mg/kg/day was started on day 11 and was continued until the end of stem cell collection. Subsequently, another induction course was to be given with etoposide at 2 g/m 2 followed again by filgrastim at 10 mg/kg/day for stem cell collection. Owing to the additional in vivo purging effect, the second graft was preferentially to be used for transplantation. At least 4 Â 10 6 CD34 þ cells/kg body weight (b.w.) had to be collected to provide for two stem cell transplantations.
Stem cell collection
As soon as the CD34 þ cell count exceeded 10/ml, PBPCs were collected using a blood cell separator (Spectra, COBE BCT Inc., Lakewood, CO, USA) with a semiautomated mononuclear cell collection program. The separation was continued until the necessary amount of CD34 þ cells was collected or until the number of circulating CD34 þ cells fell below the 10/ml threshold. If possible, peripheral veins were used; otherwise, a central venous catheter was placed in the internal jugular vein. Blood flow was between 50 and 90 ml/min, and the separation volume was the 2.5-fold of the blood volume. The ration of whole blood to anticoagulation ratio was kept regulated at 18:1, using mixed anticoagulation with 3000 IU heparin to 600 ml ACDA (Fresenius, Hemocare). Cells were mixed with DMSO at a final concentration of 10% in freezing bags (Consarctic), subjected to controlled-rate freezing (BV-25, Consarctic) and stored in liquid nitrogen under controlled standard conditions.
High-dose treatment
The first high-dose therapy consisted of melphalan 140 mg/ m 2 , given on day À4 as an i.v. infusion over 30 min, and treosulfan 30 g/m 2 , given on day À3 as an i.v. infusion over 24 h. After the transplantation of at least 2 Â 10 6 CD34 þ cells/kg b.w. on day 0, filgrastim was given s.c. at 5 mg/kg/ day from day þ 1 until neutrophil recovery 41.5/nl. The second high-dose therapy course was to be given 8-12 weeks after the first one. It contained treosulfan and thiotepa. Treosulfan was split into daily doses of 10 g/m 2 , and was given on days À5, À4, and À3, each time as an i.v. infusion over 2 h, yielding a total dose of 30 g/m 2 /day. It was planned to escalate the total dose of treosulfan in both high-dose cycles to 39 and 48 g/m 2 . Thiotepa was split into daily doses of 250 mg/m 2 , and was given on days À5, À4, and À3, each time as i.v. infusion over 60 min, yielding a total dose of 750 mg/m 2 /day. Autologous peripheral blood stem cell transplantation followed on day 0, and filgrastim was given as described above.
Study design and toxicity evaluation
One principle goal of the study was to evaluate doselimiting toxicities (DLT) and to determine the MTD of high-dose treosulfan in combination with either melphalan or thiotepa. During hospitalization, clinical and laboratory side effects were monitored daily and analyzed according to the CTC criteria of the National Cancer Institute (version 3.0). DLT was defined as any of the following toxicities: nephrotoxicity Xgrade 2, neurotoxicity Xgrade 2, other nonhematological toxicity Xgrade 3 (excluding alopecia, nausea/vomiting, infections, mucositis grade 4 shorter than 7 days, and diarrhea grade III). The MTD was defined as one dose level below the level at which greater than or equal to two of three or three of six patients experienced DLT, respectively.
Response evaluation
The other principle goal of the study was to evaluate the efficacy of the treatment at the MTD. Complete restaging was performed including clinical and laboratory workup as well as a CT scan after the completion of the two sequential induction courses, immediately before the 2nd high-dose cycle and 2 months after the last HDT. Complete remission was defined as disappearance of all lymphoma manifestations for at least 8 weeks. Partial response was defined as a more than 50% reduction of all evaluable tumor lesions for a duration of at least 8 weeks. Time to progression and survival time were calculated from the date of entry into the study protocol.
Follow-up visits were scheduled for every 3 months during the first year, every 4 months during the second year, and every 6 months thereafter. In addition to clinical and laboratory testing, CT scans were performed twice a year in the first 2 years and once a year thereafter.
Statistics
The influence of relapse situation (refractory and early relapse vs late relapse) on the achievement of complete remission was tested with Fisher's exact test. Survival curves were calculated according to the Kaplan-Meier method. Comparison of survival curves was made by the log-rank test. (Table 1) In all, 21 patients with a median age of 51 (25-60) years were included in the study. Three patients were refractory to the primary treatment, 11 patients had early and seven patients had late relapse. Four patients had peripheral Tcell lymphoma; all other patients had B-cell lymphoma. For primary treatment, 14 patients had received radiotherapy in addition to chemotherapy. One patient had front-line therapy with three intensified CHOEP regimens and PBSC support.
Results
Patient characteristics
Initial cytoreductive treatment with DexaBEAM was given to 21 patients followed by one to four PBPC aphereses (mean 2.3) in 12 patients starting between days 18 and 24 (median 20) of the cycle. The median yield was 7.3 (range 1.7-21.9) Â 10 6 CD34 þ cells per kg b.w. In four patients, stem cell collection had been performed earlier during the 1st CR and was not repeated. In three patients, stem cell collection was postponed due to grade 3 infection at the time of their CD34 þ cell peak levels. In these patients, apheresis was performed after etoposide treatment only. Two patients progressed under DexaBEAM and discontinued the study before PBPC apheresis. One patient developed secondary acute myeloid leukemia after PBPC apheresis and did not proceed to autologous transplantation.
A second cytoreductive therapy cycle with etoposide was given to 15 patients. One patient received an alternative MTX-containing polychemotherapy regimen instead of monotherapy with etoposide due to progression after DexaBEAM. In eight patients, two stem cell collections were performed between days 11 and 20 (median 15) of etoposide treatment. The median yield was 4.6 (range 0.8-32.6) Â 10 6 CD34 þ cells per kg.
1st High-dose therapy (Table 2a) A total of 16 patients received high-dose therapy with treosulfan and melphalan. The autologous peripheral blood stem cell transplants contained a median of 4. 2nd High-dose therapy (Table 2b) At 6 to 11 weeks (mean 8.3) after the 1st high-dose therapy, nine of 16 patients received a 2nd high-dose therapy. Of the remaining seven patients, four had progressed after the 1st HDT, and three patients refused a 2nd HDT. The patients who continued the study received a median of 3.5 (range 1.7-32.6) Â 10 6 CD34 þ cells per kg b.w. Grade 4 leukopenia and thrombocytopenia was seen in all patients and hematological recovery occurred after a mean of 9.6 days (range 7-13 days) for 41/nl leukocytes and after a mean of 13.0 days (range 9-17 days) for 425/nl platelets. Unfortunately, two patients died at days þ 17 and þ 19, both with pneumonia and grade 4 sepsis. One of these patients had previously undergone three high-dose regimens during front-line therapy. In addition, the interval between the beginning of the first and the second HDT was High-dose treosulfan in relapsed high-grade lymphoma M Koenigsmann et al only 6 weeks, which may have contributed to an increased susceptibility towards infectious complications. Another three patients developed grade 3 neutropenic fever. One of these patients experienced a reversible grade 3 re-entry tachycardia during septicemia on day þ 9, which was pharmacologically controlled by an i.v. bolus of adenosine. Another two patients suffered from grade 3 vomiting with or without diarrhea. One patient showed a reversible grade 3 ALAT elevation only on day -1. Throughout the study no VOD occurred. Taking together the two treatment-related deaths and the observed re-entry tachycardia during the 2nd HDT, there were three DLT among the nine patients who received both high-dose regimens. It was therefore decided not to escalate the treosulfan dosage and to consider 30 g/m 2 of treosulfan as the MTD in this tandem setting.
Response (Table 3)
Altogether nine of 21 patients reached CR (42.8%). In two of these patients, CR was documented after the etoposide course. Six patients entered CR after the 1st, and one patient after the 2nd high-dose therapy course. Further analysis revealed that none of the three patients with refractory disease, and only three of 11 patients with early relapse ever reached CR. In contrast, six of seven patients with late relapse (85%) entered CR. Fisher's exact test showed a significant difference between the poor risk group (refractory disease and early relapse) and the low-risk group (late relapse) with respect to the achievement of CR (P ¼ 0.017). Five of nine patients in CR (23.8% of the total study group) remain progression free after 25 to 48 months (median 35 months).
Overall survival (Figure 1)
After a median follow-up time of up to 24 months (range 18-49 months), the Kaplan-Meier plot showed a probability of survival of 46%. The curves of overall survival were significantly different for patients with late vs early relapse or refractory disease (P ¼ 0.0022). The probability of long-term survival was 71.4% after a follow-up time of at 
Discussion
To the best of our knowledge, this is the first published clinical study using high-dose treosulfan and autologous stem cell transplantation in a lymphoma patient population. Within a phase I trial, testing high-dose treosulfan, one CR and one PR have been previously described among two non-Hodgkin's lymphoma patients, in addition to one PR in a patient with Hodgkin's lymphoma. 12 Treosulfan was the major component of this protocol since it was the only drug used in both high-dose regimens. Nevertheless, it is hard to appreciate its exact role since it was combined with either melphalan or thiotepa. While melphalan alone is very potent in the treatment of myeloma, there is little data on its single-drug activity in high-grade lymphoma. A recently published comparative study tested melphalan vs cyclophosphamide in a BCNU-, etoposide-, and cytarabine-based protocol. The melphalancontaining regimen seemed to be more toxic to the gastrointestinal tract; however, the antilymphoma activity appeared to be similar for both combinations. 17 High-dose thiotepa is used in combination protocols with other alkylating drugs like busulfan and cyclophosphamide for patients with lymphoma or multiple myeloma. 18, 19 The only way to assess the contribution of a single drug is to compare different combination regimens for efficacy and toxicity. This is a general problem in treatment situations in which combination protocols are used.
The rationale to choose a tandem high-dose approach was derived from our intention to combine treosulfan with only one other cytotoxic agent at the same time. In order to avoid undertreatment, a second high-dose cycle was added. Although one patient entered CR only after the 2nd HDT, this strategy did not allow to conclude whether the response duration in our patients was primarily due to the activity of a single high-dose regimen or to the entire tandem highdose approach.
The dosage of treosulfan of 30 g/m 2 for each cycle was extrapolated from a phase I trial where 47 g/m 2 was the MTD for a single, stem cell supported, therapy with treosulfan only. Since there was no data on tandem transplants with treosulfan, it was decided to start with a total dosage of no more than 60 g/m 2 for both therapy cycles. Given a total of three DLT in nine patients who had received tandem therapy, this decision has proven to be reasonable. Owing to the sequential application of two high-dose regimens, however, this protocol did not allow the evaluation of the MTD of treosulfan within a single high-dose combination protocol.
With respect to the bioequivalency of our doses of treosulfan in comparison to other alkylators in hematologic malignancies, one study has compared the in vitro activity of treosulfan and melphalan.
14 At a concentration of 100 mmol/l, both drugs induced cell death in approximately 60% of primary myeloma cells. Similar concentrations were reached in the serum of patients treated with a melphalan dosage of 200 mg/m 2 . However, the serum levels of patients who were treated with 30-47 g/m 2 treosulfan were several fold higher. 12 With all due caution, it can therefore be assumed that the biologic activity of the treosulfan dosage Table 3 Response to study treatment High-dose treosulfan in relapsed high-grade lymphoma M Koenigsmann et al used in our study was not inferior to the activity of other alkylators. Lee et al 20 showed a 28% incidence of VOD in patients receiving a combination of busulfan, melphalan, and thiotepa. At variance, we did not observe any VOD in our patients treated with treosulfan. On the other hand, two fatal infectious complications in our study after the second high-dose cycle was a serious problem. In both cases, the interval between the two high-dose treatments was short with only 6 weeks. One patient carried an additional toxic risk since he had previously received three dose-intensified regimens with autologous transplantation during primary therapy. These additional risk factors should be avoided in the future. To this purpose, the interval between the high-dose regimens should be extended to at least 8 weeks, and patients with prior high-dose therapy should be excluded from tandem transplantation. We do think that tandem transplantation is to be further explored in this setting, and it should currently be restricted to those patients who reach only a PR after the first HDT. Interestingly, one of our patients with early relapse reached CR only after the second high-dose therapy, and she is in continuous CR for meanwhile 33 months.
Another toxic problem was mucositis, which is a strain on the patient's quality of life and is associated with a high risk of infections. While etoposide is one of the most efficient drugs for stem cell mobilization 21, 22 and a component of combination protocols in high-grade lymphoma, 23 its use is clearly associated with the occurrence of post-transplant mucositis. 24 The observation of two cases of grade 4 mucositis in our series is consistent with this finding and will be taken into account for future trials. The nonhematologic DLTs observed during a phase I trial with treosulfan monotherapy were diarrhea, mucositis, acidosis, reversible skin reactions, vomiting, and headache. 12 It remained unclear as to whether the observed re-entry tachycardia during neutropenic fever in one of our patients after the 2nd HDT was due to a toxic effect or due to a preexisting cardiac problem.
Confirming the early data of Philip and of the PARMA trial, 1, 25 we saw a superior outcome of patients with late relapse reaching a CR rate in six of seven cases (85.7%) and an ongoing median survival of 35 months (25-48 months) in five of seven patients (71.4%). Owing to the small number, however, this finding has to be looked at with caution.
The main problems in our series arose in patients with primary refractory disease and early relapse. In keeping with the data of Guglielmi et al, 25 only three of 11 patients with early relapse entered CR. Disease progression prevented four patients each from proceeding to the 1st or to the 2nd high-dose therapy cycle. Two of our patients were chemorefractory at the time of transplantation, but were able to receive high-dose therapy. One of these patients progressed further. However, the other patient reached complete remission after the 1st HDT, and he even received a 2nd HDT. These data are too limited to draw conclusions on the activity of our protocol for patients who are chemoresistent at relapse, but further study of this question is urgently needed. Interestingly, Vose et al 26 reported data from the ABMTR (Autologous Blood and Marrow Transplant Registry) where patients who never achieved remission with conventional therapy had a 44% CR rate, and a probability of progression-free and overall survival at 5 years after transplantation of 31%.
A contribution for the treatment of refractory disease might be given by allogeneic transplantation due to the graft-versus lymphoma effect. [27] [28] [29] Further, the monoclonal antibody rituximab has the potential to improve the treatment results in relapsed or refractory B-cell lymphoma on several levels; first, at initial cytoreductive treatment for rapid induction of remission, second, for in vivo stem cell purging, and lastly, during or after HDT for the maintenance of remission. [30] [31] [32] In conclusion, the feasibility to include treosulfan into a high-dose combination regimen has been demonstrated. Further, we have defined the MTD of treosulfan in this (46%) for all patients entering the study (a), and separately for patients with late relapse (at least 1 year from 1st diagnosis) or early relapse and refractory disease (b). The course of the curves is significantly different (logrank test, P ¼ 0.0022). Probability of long-term remission (at least 24 months) is significantly higher for patients with late relapse (71.4%) compared to patients with early relapse or refractory disease (21.4%, Po0.05).
tandem setting. Our data show low organ toxicity and promising activity in patients, especially those with late relapse of aggressive lymphoma. Therefore, further evaluation of treosulfan in patients with lymphoma and other hematologic malignancies is warranted.
